Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 2/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103845 | 0.83 | LMNA (0.61) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL30815826 | 0.83 | LMNA (0.61) | LMNAGLAPOLBGAASMARCA2 | |
| Hydrochloric Acid SCHEMBL3107661 | 0.82 | LMNA (0.64) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL8109087 | 0.80 | LMNA (0.51) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL10731367 | 0.72 | ALDH1A1 (0.38) | LMNAKMT2ANMT1KDM4ERXFP1 | |
| SCHEMBL5290618 | 0.68 | LMNA (0.42) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL14156551 | 0.67 | ALDH1A1 (0.35) | LMNAGLAGAAKDM4ERXFP1 | |
| SCHEMBL13941828 | 0.66 | LMNA (0.68) | LMNAGLAPOLBGAASMARCA2 | |
| SCHEMBL2757284 | 0.65 | DHFR (0.45) | POLBKDM4E | |
| SCHEMBL3921653 | 0.64 | GLA (0.64) | LMNAGLAPOLBGAASMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021891-A2 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | ADRB1, ADRB2, ADRB3 | LMNA 972/4885GLA 1192/4885POLB 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.